RxDoctor Payments Data

Fernando Calero Baquerizo, MD

Internal Medicine · Providence, RINPI 1407197395

Payments from drug & device makers

$1,476in general payments, 2019–2025

Across 107 payments — averaging $13.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$245
  • AbbVie$197
  • Novo Nordisk$157
  • GSK$142
  • AstraZeneca$116
  • Amgen$114
  • plus $504 from 14 others

What the payments were for

  • Food & beverage$1,476100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,476 in reported general payments places this provider in the 80th percentile of 808 internal medicine providers in Rhode Island.

See all internal medicine providers in Rhode Island

Medicare billing

Part B allowed, 2024
$26,325
Medicare patients
145
Services billed
323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GenvoyaElviteg/Cob/Emtri/Tenof Alafen133$552,523
BiktarvyBictegrav/Emtricit/Tenofov Ala84$331,182
JardianceEmpagliflozin91$74,799
EliquisApixaban81$67,009
TrulicityDulaglutide55$61,592
Darunavir61$53,460
DescovyEmtricitabine/Tenofov Alafenam21$51,445
TriumeqAbacavir/Dolutegravir/Lamivudi12$41,031
OzempicSemaglutide29$26,068
IsentressRaltegravir Potassium11$25,467
PifeltroDoravirine12$20,130
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$17,720
Tresiba Flextouch U-200Insulin Degludec18$12,569
Tresiba Flextouch U-100Insulin Degludec13$7,072
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$4,293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$50$74,79991 claims
PfizerEliquis$71$67,00981 claims
Lilly USA, LLCTrulicity$26$61,59255 claims
MerckIsentress, Pifeltro$37$45,59623 claims
Novo NordiskOzempic$157$26,06829 claims
GSKTrelegy Ellipta$142$17,72027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 808 internal medicine providers in Rhode Island.

Other internal medicine in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →